Fluvastatin inhibits the expression of fibronectin in human peritoneal mesothelial cells induced by high-glucose peritoneal dialysis solution via SGK1 pathway

Clinical and Experimental Nephrology

Volumn 19, Issue 3, 2015, Pages 336-342

  Zhang, Li ^a   Liu, Jia ^a   Liu, Yanchun ^a   Xu, Yaguang ^a   Zhao, Xiufen ^a   Qian, Jun ^a   Sun, Bin ^a   Xing, Changying ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Fibronectin; Fluvastatin; High glucose peritoneal dialysis solution; Human peritoneal mesothelial cells; Serum and glucocorticoid inducible kinase 1

Indexed keywords

FIBRONECTIN; FLUINDOSTATIN; GLUCOSE; GSK 650394; PERITONEAL DIALYSIS FLUID; PROTEIN SERINE THREONINE KINASE INHIBITOR; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; DIALYSIS FLUID; FUSED HETEROCYCLIC RINGS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMEDIATE EARLY PROTEIN; INDOLE DERIVATIVE; MESSENGER RNA; MONOUNSATURATED FATTY ACID; PROTEIN SERINE THREONINE KINASE; SERUM-GLUCOCORTICOID REGULATED KINASE;

ARTICLE; CELL CONTACT; CELL CULTURE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MESOTHELIUM CELL; PATHOGENESIS; PERITONEAL FIBROSIS; PERITONEAL MESOTHELIAL CELL; PERITONEUM CELL; PHENOTYPE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; METABOLISM; PERITONEUM;

BENZOATES; BICYCLO COMPOUNDS, HETEROCYCLIC; CELLS, CULTURED; DIALYSIS SOLUTIONS; EPITHELIAL CELLS; FATTY ACIDS, MONOUNSATURATED; FIBRONECTINS; GENE EXPRESSION; GLUCOSE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMEDIATE-EARLY PROTEINS; INDOLES; PERITONEUM; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84931003594     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-014-0991-0     Document Type: Article

References (27)

1. Davies SJ, Phillips L, Griffiths AM, et al. What really happens to people on long-term peritoneal dialysis? Kidney Int. 1998;54:2207–17.
2. Krediet RT. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int. 1999;55:341–56.
3. Davies SJ, Phillips L, Naish PF, et al. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001;12:1046–51.
4. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int. 2004;66:2437–45.
5. Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005;288:F433–42.
6. Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470–9.
7. Vriese ASD, Flyvbjerg A, Mortier S, et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol. 2003;14:2109–18.
8. Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470–9.
9. Wiliams JD, Topley N, Craig KJ, et al. The Euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int. 2004;66:408–18.
10. Del Peso G, Ferna´ndez-Reyes MJ, Hevia C, et al. Factors influencing peritoneal transport parameters during the first year on peritoneal dialysis: peritonitis is the main factor. Nephrol Dial Transplant. 2005;20:1201–6.
11. Fillon S, Klingel K, Warntges S, et al. Expression of the serine/threonine kinase hSGK1 in chronic viral hepatitis. Cell Physiol Biochem. 2002;12:47–54.
12. Friedrich B, Warntges S, Klingel K, et al. Up-regulation of the human serum and glucocorticoid-dependent kinase 1 in glomerulonephritis. Kidney Blood Press Res. 2002;25:303–7.
13. Wa¨rntges S, Klingel K, Weigert C, et al. Excessive transcription of the human serum and glucocorticoid dependent kinase hSGK1 in lung fibrosis. Cell Physiol Biochem. 2002;12:135–42.
14. Lang F, Klingel K, Wagner CA, et al. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci USA. 2000;97:8157–62.
15. Yamahara H, Kishimoto N, Nakata M, et al. Direct aldosterone action as a profibrotic factor via ROS-mediated SGK1 in peritoneal fibroblasts. Kidney Blood Press Res. 2009;32:185–93.
16. Nishimura H, Ito Y, Mizuno M, et al. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol Renal Physiol. 2008;294:1084–93.
17. Okazaki A, Mori Y, Nakata M, et al. Peritoneal mesothelial cells as a target of local aldosterone action: upregulation of connective tissue growth factor expression via serum- and glucocorticoid- inducible protein kinase 1. Kidney Blood Press Res. 2009;32(3):151–60.
18. Li ZM, Ma JF, Wang LN. Influence of atorvastatin on the expression of monocyte chemoattractant protein-1 in peritoneal mesothelial cells by high glucose. Zhonghua Yi Xue Za Zhi. 2007;87(38):2677–80.
19. Carrión B, Pérez-Martínez FC, Monteagudo S, et al. Atorvastatin reduces high glucose toxicity in rat peritoneal mesothelial cells. Perit Dial Int. 2011;31(3):325–31.
20. Lee JE, Oh KH, Choi KH, et al. Statin therapy is associated with improved survival in incident peritoneal dialysis patients: propensity-matched comparison. Nephrol Dial Transplant. 2011;26(12):4090–4.
21. Waldegger S, Klingel K, Barth P, et al. h-SGK serine-threonine protein kinase gene as transcriptional target of transforming growth factor beta in human intestine. Gastroenterology. 1999;116:1081–8.
22. Klingel K, Warntges S, Bock J, et al. Expression of cell volume-regulated kinase h-sgk in pancreatic tissue. Am J Physiol Gastrointest Liver Physiol. 2000;279:G998–1002.
23. Bistrup C, Thiesson HC, Jensen BL, et al. Reduced activity of 11 beta-hydroxysteroid dehydrogenase type 2 is not responsible for sodium retention in nephrotic rats. Acta Physiol Scand. 2005;184:161–9.
24. Steffel J, Latini RA, Akhmedov A, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation. 2005;112:2002–11.
25. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47:648–57.
26. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95–105.
27. Mizuno H, Nishida E. The ERK MAP kinase pathway mediates induction of SGK (serum- and glucocorticoid-inducible kinase) by growth factors. Genes Cells. 2001;6:261–8.